Episode 68: MS & AI with Dr. Chase Spurlock, CEO of iQuity
RealTalk MS11 Des 2018

Episode 68: MS & AI with Dr. Chase Spurlock, CEO of iQuity

Artificial intelligence is about to change the entire healthcare landscape. And that might very well include how MS is diagnosed, treated, and managed. It's even beginning to impact the way some MS research is being conducted. My guest is the founder and CEO of iQuity, Dr. Chase Spurlock. iQuity is using its expertise in machine learning to improve patient care, drive the creation of new therapies, and reduce the costs associated with managing chronic illness, including multiple sclerosis. We're also talking about the important but sometimes overlooked difference between MS facts and MS beliefs. We'll tell you about the safety alert that the FDA has issued for Lemtrada, and new survey research from the MS Society in the UK that shows the majority of people living with MS are living with feelings of loneliness and isolation. You'll hear about new study data that shows the gender differences in MS have some age-related fine points that are worth noting, and we'll tell you about a Phase 3 clinical trial that's looking at the effectiveness of high-dose biotin in slowing or stopping MS progression for people living with progressive MS. We have a lot to talk about! Are you ready for RealTalk MS?! ___________

The Difference Between MS Facts & MS Beliefs 0:22

How AI is About to Disrupt Healthcare 4:21

FDA Issues a Safety Alert for Lemtrada 7:40

MS Society in the UK Survey Research Shows 3 in 5 People Living with MS are Living with Loneliness 9:51

Gender Differences in MS Vary with Age & MS Subtype 13:40

MedDay Phase 3 Clinical Trial for Progressive MS Fully Enrolled 15:55

My Interview with iQuity CEO, Dr. Chase Spurlock 17:50

___________

LINKS
If your podcast app doesn't allow you to click on these links, you'll find them in the show notes
in the RealTalk MS app or at www.RealTalkMS.com

Download the RealTalk MS App for iOS

Download the RealTalk MS App for Android

FDA Warns About Rare But Serious Risks of Stroke & Blood Vessel Wall Tears with Multiple Sclerosis Drug Lemtrada

Age-Dependent Variation of Female Preponderance Across Different Phenotypes of Multiple Sclerosis: A Retrospective Cross-Sectional Study

iQuity

Give RealTalk MS a Rating & Review

___________

Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.

RealTalk MS Episode 68
Hosted By: Jon Strum
Guest: Dr. Chase Spurlock

Tags: MS, MultipleSclerosis, MS, RealTalkMS, mssocietyUK, AI, Lemtrada, MedDay, Biotin, iQuity

Episoder(505)

Episode 443: The 2026 ACTRIMS Forum (Part 3) with Dr. Helen Tremlett, Dr. Ilana Katz Sand, and Kathy Smith

Episode 443: The 2026 ACTRIMS Forum (Part 3) with Dr. Helen Tremlett, Dr. Ilana Katz Sand, and Kathy Smith

Welcome back to the third and final part of our coverage of the 2026 ACTRIMS Forum. This week's episode bridges the gap between groundbreaking clinical research and the nuanced reality of living with ...

23 Feb 35min

Episode 442: The 2026 ACTRIMS Forum (Part 2) with Dr. Jeffrey Cohen, Dr. Daniel Ontaneda, and Kristine Werner Ozug

Episode 442: The 2026 ACTRIMS Forum (Part 2) with Dr. Jeffrey Cohen, Dr. Daniel Ontaneda, and Kristine Werner Ozug

Welcome back to Part Two of our coverage of the 2026 ACTRIMS Forum. This week, we shift our focus to emerging therapies and clinical insights that are re-shaping the future of MS care. From the latest...

16 Feb 44min

Episode 441: The 2026 ACTRIMS Forum with Dr. Manuel Friese, Dr. Amit Bar-Or, and Dr. Haritha Desu

Episode 441: The 2026 ACTRIMS Forum with Dr. Manuel Friese, Dr. Amit Bar-Or, and Dr. Haritha Desu

Last week, over 1,400 scientists and clinicians gathered in San Diego, California, at the 2026 Americas Committee for Treatment and Research in Multiple Sclerosis annual meeting, better known as the A...

9 Feb 33min

Episode 440: An MS Specialist's Response to the FDA with Dr. William Conte

Episode 440: An MS Specialist's Response to the FDA with Dr. William Conte

This past December, the FDA issued a Complete Response Letter to drug manufacturer Sanofi in response to Sanofi's application seeking approval for Tolebrutinib, the first in a new category of investig...

2 Feb 39min

Episode 439: Preventing MS with Dr. Bruce Bebo

Episode 439: Preventing MS with Dr. Bruce Bebo

The first coordinated global research strategy to prevent MS has been announced. This week, Dr. Bruce Bebo, the National MS Society's Executive Vice President and Chief Research & Medical Affairs Offi...

26 Jan 32min

Episode 438: The Discovery of 2 MS Subtypes with Dr. Arman Eshaghi

Episode 438: The Discovery of 2 MS Subtypes with Dr. Arman Eshaghi

One of the more confusing aspects of MS is that it can present differently from one person to the next. A research team at University College London may have uncovered a reason for that when they iden...

19 Jan 29min

Episode 437: Remembering David Mitchell

Episode 437: Remembering David Mitchell

I don't have to remind anyone who listens to this podcast that the cost of MS disease-modifying therapies is obscenely high. And we're not just talking about relatively new medications. Older medicati...

12 Jan 29min

Episode 436: 3 Questions Your Neurologist Should Be Asking Themselves with Dr. Leorah Freeman

Episode 436: 3 Questions Your Neurologist Should Be Asking Themselves with Dr. Leorah Freeman

Scientists are expanding our understanding of MS at an unprecedented pace. This week, Dr. Leorah Freeman discusses why, as new discoveries and medications enter clinical practice, neurologists and MS ...

5 Jan 34min

Populært innen Helse

fastlegen
lydartikler-fra-aftenposten
hvordan-har-du-det-mann
rss-gukild-johaug
psykodrama
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
leger-om-livet
rss-garne-damer
foreldreradet
hjernesterk
bak-fasaden-en-reise-i-livet-med-sykepleier-ine
hormonelle-frida
g-punktet
morten-ramm-lar-kakla-ga-til-du-sovner
klimaks
rss-lopedrommen
helsetipspodden
rss-kull
sinnsyn
biohacking-girls-din-podcast-for-optimal-helse